Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
NCT04267939 · Bayer · PHASE1 · terminated · last registry update 2023-12-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “There was no anticipated benefit of the experimental combination as tested over available standard therapies; therefore Sponsor has decided to terminate the investigation.” | – | Registry record, Bayer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ATR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-13Phase 3 first posted: National Cancer Institute (NCI), Ceralasertib + Durvalumab (NCT06732401)
- 2024-11-29Results posted on the registry: Merck KGaA, Darmstadt, Germany, Berzosertib (NCT03309150)
- 2024-11-22Results posted on the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, [14C]Berzosertib + Berzosertib (NCT05246111)
- 2024-11-13Results posted on the registry: National Cancer Institute (NCI), Berzosertib + Topotecan Hydrochloride (NCT03896503)
- 2024-09-26Results posted on the registry: EMD Serono Research & Development Institute, Inc., Berzosertib + Berzosertib (NCT04768296)
- 2024-08-12Results posted on the registry: University of Michigan Rogel Cancer Center, Olaparib + AZD6738 (NCT03787680)
- 2024-06-25Results posted on the registry: AstraZeneca, Ceralasertib (NCT04564027)
- 2023-10-17Results posted on the registry: National Cancer Institute (NCI), Berzosertib + Cisplatin (NCT02567409)
- 2023-07-07Results posted on the registry: Massachusetts General Hospital, M6620 (NCT03718091)
- 2023-05-19Results posted on the registry: National Cancer Institute (NCI), Berzosertib (NCT02589522)
- 2023-03-16Results posted on the registry: EMD Serono Research & Development Institute, Inc., M4344 10 mg BIW + M4344 20 mg BIW (NCT02278250)
- 2022-12-28Results posted on the registry: Joseph Paul Eder, AZD2281 + AZD5363 (NCT02576444)
- 2022-12-28Also stopped (terminated): Joseph Paul Eder, AZD2281 + AZD5363 (NCT02576444)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision